dx 8951 has been researched along with Carcinoma, Oat Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A | 1 |
| Ishida, T; Mori, M; Nishio, K; Nomoto, T; Saijo, N | 1 |
| Ejima, A; Imagawa, S; Ishii, M; Iwahana, M; Minami, M; Mitsui, I; Tohgo, A | 1 |
| Saijo, N | 1 |
1 review(s) available for dx 8951 and Carcinoma, Oat Cell
| Article | Year |
|---|---|
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
3 other study(ies) available for dx 8951 and Carcinoma, Oat Cell
| Article | Year |
|---|---|
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water | 1997 |
Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water | 1998 |
Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Small Cell; Cisplatin; DNA Primers; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; Fluorouracil; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; In Vitro Techniques; Inactivation, Metabolic; Isoenzymes; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2000 |